S&P 500

5.460,48

-0,41%

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

MXCN

Maxcyte (MXCN)

Maxcyte Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:LSE:MXCN

1

Data	Hora	Fonte	Título	Código	Companhia
12/03/2024	17:05	UK Regulatory	MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance	LSE:MXCN	Maxcyte Inc
04/03/2024	18:05	UK Regulatory	MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results	LSE:MXCN	Maxcyte Inc
09/02/2024	10:05	UK Regulatory	MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences	LSE:MXCN	Maxcyte Inc
30/01/2024	10:05	UK Regulatory	MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers	LSE:MXCN	Maxcyte Inc
09/08/2021	03:00	PR Newswire (US)	MaxCyte Signs Clinical and Commercial License with Sana Biotechnology	LSE:MXCN	Maxcyte Inc
30/07/2021	12:07	PR Newswire (US)	DLA Piper advises underwriters of MaxCyte's upsized US IPO	LSE:MXCN	Maxcyte Inc
30/07/2021	00:05	PR Newswire (US)	MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market	LSE:MXCN	Maxcyte Inc
26/07/2021	08:49	PR Newswire (US)	MaxCyte Announces Launch of Offering and Application to List on the Nasdaq Global Market	LSE:MXCN	Maxcyte Inc
12/07/2021	03:00	PR Newswire (US)	MaxCyte Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual Listing	LSE:MXCN	Maxcyte Inc
12/07/2021	03:00	PR Newswire (US)	Financial information in the Form S-1 registration statement and Change to Board of Directors	LSE:MXCN	Maxcyte Inc
14/05/2021	03:00	PR Newswire (US)	Proposed Dual-Listing on Nasdaq	LSE:MXCN	Maxcyte Inc